MAI Capital Management lessened its position in Johnson & Johnson (NYSE:JNJ) by 1.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 149,066 shares of the company’s stock after selling 2,128 shares during the period. Johnson & Johnson comprises 1.3% of MAI Capital Management’s portfolio, making the stock its 14th largest holding. MAI Capital Management’s holdings in Johnson & Johnson were worth $19,720,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of JNJ. State Street Corp increased its position in Johnson & Johnson by 4.3% during the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after purchasing an additional 6,656,371 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in Johnson & Johnson by 4.2% during the second quarter. Schwab Charles Investment Management Inc. now owns 11,623,639 shares of the company’s stock worth $1,537,692,000 after purchasing an additional 473,300 shares during the last quarter. Fisher Asset Management LLC increased its position in Johnson & Johnson by 3.7% during the second quarter. Fisher Asset Management LLC now owns 11,499,415 shares of the company’s stock worth $1,521,258,000 after purchasing an additional 405,517 shares during the last quarter. Clearbridge Investments LLC increased its position in Johnson & Johnson by 3.4% during the first quarter. Clearbridge Investments LLC now owns 9,543,827 shares of the company’s stock worth $1,188,684,000 after purchasing an additional 310,831 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its position in Johnson & Johnson by 1.5% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,068,979 shares of the company’s stock worth $1,067,445,000 after purchasing an additional 120,037 shares during the last quarter. 65.91% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson (NYSE:JNJ) opened at $139.98 on Friday. The firm has a market cap of $376,059.06, a price-to-earnings ratio of 19.61, a PEG ratio of 2.84 and a beta of 0.81. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $144.35.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.80 by $0.10. The business had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.68 earnings per share. analysts anticipate that Johnson & Johnson will post 7.28 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be paid a $0.84 dividend. The ex-dividend date is Monday, November 27th. This represents a $3.36 annualized dividend and a dividend yield of 2.40%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.

Several equities analysts recently commented on the stock. J P Morgan Chase & Co upped their price target on shares of Johnson & Johnson from $140.00 to $148.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 16th. Citigroup assumed coverage on shares of Johnson & Johnson in a research report on Monday, September 25th. They set a “neutral” rating and a $140.00 price target for the company. Jefferies Group set a $145.00 price target on shares of Johnson & Johnson and gave the stock a “hold” rating in a research report on Tuesday, August 15th. BMO Capital Markets reaffirmed a “positive” rating and set a $152.00 price target (up previously from $145.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. Finally, Royal Bank Of Canada upped their price target on shares of Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 18th. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $144.59.

TRADEMARK VIOLATION WARNING: This piece was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/03/mai-capital-management-has-19-72-million-stake-in-johnson-johnson-jnj.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.